This technology describes a mouse model of Gaucher disease (GD) and Parkinson’s Disease (PD), consisting of a p.E326K mutation in the Glucocerebrosidase (GBA) gene.
Gaucher disease (GD) is a common autosomal recessive lysosomal storage disorder caused by biallelic mutations in the Glucocerebrosidase (GBA) gene. Mutations in this gene is also associated with increased risk for Parkinson’s Disease and dementia with Lewy bodies (DLB). Currently there is no treatment for neurological symptoms in GD and PD/DLB, but novel drugs are under development. There is need for an animal model to evaluate drug candidates preclinically and study the pathobiology behind these diseases.
This technology describes a Preclinical Gba p.E326K mouse model for biomarker and small molecule screening, discovery, and therapeutic development for Gba p.E326K Modifier associated Gaucher disease (GD), Gba p.E326K associated Parkinson’s Disease (PD), Dementia with Lewy Bodies (DLB). The variant was introduced using CRISPR-Cas9 genome editing, and the model was confirmed by behavioral characterization to assess motor and cognitive function.
This technology has been validated in mice.
Patent Pending
IR CU23198
Licensing Contact: Kristin Neuman